BEIJING, Sept. 25, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the hiring of Dr. Jinyou Zhang as Senior Vice President to lead its bioprocess development and manufacturing. His responsibilities include overseeing biologics GMP manufacturing for clinical and commercial productions, implementing process design, ensuring quality control, interfacing with CMOs and CROs, and building up facilities. In addition, he will be leading the recruitment of top talents to the team. Dr. Zhang will report to CEO, John V. Oyler.
"I am very pleased to welcome Jinyou to our team at this critical stage in our growth," said John V. Oyler, CEO of BeiGene. "His breadth of experience and expertise, particularly in clinical/commercial manufacturing of biologics, process optimization, contract manufacturing, and regulatory requirements will be invaluable to our current and future needs. As our pipeline continues to make progress, so has the need to carefully plan for, monitor, and direct compliant manufacturing activities and meet quality assurance for the development of new biologics."
Dr. Zhang brings over 24 years of industry experience in bioprocessing and biomanufacturing to BeiGene. Most recently, he was the Vice President and Site Head at WuXi AppTec in Wuxi, China. Previously, Dr. Zhang was the Vice President of Process Development and Manufacturing at Immunomedics in Morris Plains, NJ, and Executive Director of Bioprocess R&D at Novavax in Gaithersburg, MD. Dr. Zhang began his career at Merck & Co. where he worked in Bioprocess R&D for 15 years. He obtained his Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology in 1991 under the supervision of Prof. Arnold Demain (Fellow of US Academy of Science, Ex-President of Society of Industrial Microbiology).
"I am excited to join the BeiGene team. I see tremendous opportunities here where I can contribute to improving the lives of patients and helping the company grow," said Dr. Zhang. "This is what attracted me to BeiGene".
BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 175+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients. For more information, please visit our website at www.beigene.com.
CONTACT: Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050 email@example.com